Thrombin generation in patients with COVID-19 with and without thromboprophylaxis

• Published in: Clinical chemistry and laboratory medicine Vol. 59; no. 7; pp. 1323 - 1330
• Main Authors: Campello, Elena, Bulato, Cristiana, Spiezia, Luca, Boscolo, Annalisa, Poletto, Francesco, Cola, Marco, Gavasso, Sabrina, Simion, Chiara, Radu, Claudia Maria, Cattelan, Annamaria, Tiberio, Ivo, Vettor, Roberto, Navalesi, Paolo, Simioni, Paolo
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 25.06.2021; Walter De Gruyter & Company
• Subjects: coagulopathy; Coronaviruses; COVID-19; Diagnosis; Hospitals; hypercoagulability; inflammation; Intensive care units; Lag time; SARS-CoV-2; Thrombin; venous thromboembolism; SARS-CoV-2; coagulopathy; hypercoagulability; inflammation; venous thromboembolism
• ISSN: 1434-6621; 1437-4331; 1437-4331
• DOI: 10.1515/cclm-2021-0108

Thrombin generation (TG) with and without thrombomodulin (TM) was evaluated in COVID-19 patients with different disease severity and thromboprophylaxis regimen, in order to understand the prothrombotic profile. We enrolled consecutive patients with confirmed diagnosis of COVID-19 admitted to Medical Departments (MD) or Intensive Care Units (ICU), and 54 healthy controls. Eighty-nine patients were included (mean age 60.4±16.1 years, 68.5% male); 33.7% admitted to ICU. Twenty-four patients (26.9%) were enrolled before thromboprophylaxis administration; 45 patients (50.6%) received standard and 20 (22.5%) intermediate sub-therapeutic dose thromboprophylaxis. Overall, patients with COVID-19 showed a TG profile comparable to that of healthy subjects (i.e. comparable peak height, endogenous thrombin potential [ETP] with and without TM). The only exception was lag time and time to peak, prolonged in COVID-19 patients vs. controls. MD patients showed a similar TG profile to healthy controls, and ICU patients showed significantly decrease ETP (p=0.030) compared to MD. As for thromboprophylaxis, TG profile was significantly increased in COVID-19 patients without thromboprophylaxis vs. controls and vs. those with thromboprophylaxis. In this latter group, ETP inhibition was significantly decreased (p=0.0003) and positively correlated with anti-Xa activity (r=0.49, p=0.0017). However, patients with thromboprophylaxis had similar TG profile vs. controls. Intermediate dose thromboprophylaxis more effectively inhibited TG in severe COVID-19 patients by increasing ETP inhibition via ETP with TM reduction vs. standard dose. COVID-19 patients showed increased TG at diagnosis. Standard thromboprophylaxis reduced TG to levels of healthy controls. Intermediate sub-therapeutic thromboprophylaxis more effectively inhibited TG by decreasing ETP with TM.